Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential

Narum, Steven M.; Le, Tram; Lê, Dao; Lee, Joanne C.; Donahue, Nathan; Yang, Wen; Wilhelm, Stefan

doi:10.1016/b978-0-12-816662-8.00004-7

Cited by 54 publications

(33 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, a combination of TGF-β inhibitor, ECM degradation enzymes, and the hormone relaxin can be used to reduce fibrosis and normalize ECM [ 282 , 283 , 318 ]. While a full discussion is beyond the scope of this review, Attia et al and Narum et al prepared excellent reviews of these techniques [ 319 , 320 ].…”

Section: Nanocarrier Platforms and Binding Strategiesmentioning

confidence: 99%

Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms

Sun

Davis

2021

Nanomaterials

View full text Add to dashboard Cite

To achieve the promise of stimuli-responsive drug delivery systems for the treatment of cancer, they should (1) avoid premature clearance; (2) accumulate in tumors and undergo endocytosis by cancer cells; and (3) exhibit appropriate stimuli-responsive release of the payload. It is challenging to address all of these requirements simultaneously. However, the numerous proof-of-concept studies addressing one or more of these requirements reported every year have dramatically expanded the toolbox available for the design of drug delivery systems. This review highlights recent advances in the targeting and stimuli-responsiveness of drug delivery systems. It begins with a discussion of nanocarrier types and an overview of the factors influencing nanocarrier biodistribution. On-demand release strategies and their application to each type of nanocarrier are reviewed, including both endogenous and exogenous stimuli. Recent developments in stimuli-responsive targeting strategies are also discussed. The remaining challenges and prospective solutions in the field are discussed throughout the review, which is intended to assist researchers in overcoming interdisciplinary knowledge barriers and increase the speed of development. This review presents a nanocarrier-based drug delivery systems toolbox that enables the application of techniques across platforms and inspires researchers with interdisciplinary information to boost the development of multifunctional therapeutic nanoplatforms for cancer therapy.

show abstract

Section: Nanocarrier Platforms and Binding Strategiesmentioning

confidence: 99%

Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms

Sun

Davis

2021

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…They found two key observations to passive targeting: (1) spontaneous accumulation of drug carrier in areas of solid tumors with leaky vascular and (2) retention of the carrier due to compromise lymphatic drainage. With these two observations, the concept of enhancing permeability and retention (EPR) effect was formed [ 128 ]. To further understand the basis of the EPR effect, we must first understand the pathophysiology of the tumor.…”

Section: Msns As Smart Drug Delivery Agentmentioning

confidence: 99%

“…Molecules smaller than 4 nm can diffuse back to the bloodstream, but the nanoparticles are impeded due to their larger particle size, thus retain in the solid tumor. This part refers to the retention of the EPR effect [ 128 , 129 ].…”

Section: Msns As Smart Drug Delivery Agentmentioning

confidence: 99%

See 1 more Smart Citation

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

show abstract

“…There are two kinds of targeted delivery, namely passive and active targeting. These strategies are aimed to deliver NPs along with their therapeutic loads to diseased organs while minimizing their accumulation in healthy tissues 11 . In the bone, passive targeting utilizes bone‐marrow capillariesʼ fenestrations 12 .…”

Section: Introductionmentioning

confidence: 99%

Targeted nanomedicines for the treatment of bone disease and regeneration

Ordikhani

Zandi

Mazaheri

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone‐targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.

show abstract

Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential

Cited by 54 publications

References 144 publications

Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms

Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Targeted nanomedicines for the treatment of bone disease and regeneration

Contact Info

Product

Resources

About